Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

5.90USD
4:00pm EDT
Change (% chg)

$0.05 (+0.85%)
Prev Close
$5.85
Open
$5.80
Day's High
$5.92
Day's Low
$5.80
Volume
6,588
Avg. Vol
25,838
52-wk High
$10.16
52-wk Low
$5.49

MNOV.OQ

Chart for MNOV.OQ

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)
No analyst recommendations are available for MNOV.OQ.

Overall

Beta: 0.53
Market Cap(Mil.): ¥22,349.85
Shares Outstanding(Mil.): 34.53
Dividend: --
Yield (%): --

Financials

  MNOV.OQ Industry Sector
P/E (TTM): -- 49.04 30.15
EPS (TTM): -36.94 -- --
ROI: -29.13 -2.17 13.05
ROE: -32.30 5.20 14.20

BRIEF-Medicinova announces positive findings from completed trial of MN-166 research

* Medicinova announces positive findings from completed trial of MN-166 (ibudilast) in methamphetamine dependence presented at the 50th winter conference on brain research Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence

* Medicinova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence

Jan 23 2017

BRIEF-Medicinova files for offering of up to 869,047 shares by selling stockholders

* Files for offering of up to 869,047 shares of common stock by the selling stockholders

Nov 29 2016

BRIEF-Medicinova Inc - expected basic, diluted loss per share for year ending Dec. 31 is $0.31

* Medicinova Inc - expected basic and diluted loss per share for year ending December 31, 2016 is $0.31 Source text (http://bit.ly/2e9YebC) Further company coverage:

Oct 26 2016

More From Around the Web

Earnings vs. Estimates